Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
University of California, Irvine
ClinicalTrials.gov Identifier:
First received: October 10, 2005
Last updated: May 4, 2006
Last verified: October 2005
  1. Implement a single-visit program (SVP) for cervix cancer prevention in clinics serving a multi-ethnic population of women;
  2. Set up an efficient system for interpretation of Pap smears for patients in the SVP that will minimize waiting time;
  3. Determine the follow-up rates and compare them between women assigned to the SVP and a usual care program (UCP);
  4. Determine satisfaction and compare it between women assigned to the SVP and the UCP;
  5. Determine the cost-effectiveness and compare it between the SVP and UCP

Condition Intervention Phase
Cervical Intraepithelial Neoplasia
Procedure: Large loop electrosurgical excision
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Single Visit Cervical Cancer Prevention Program

Resource links provided by NLM:

Further study details as provided by University of California, Irvine:

Study Start Date: July 1999
Detailed Description:
Women were recruited from underserved communities to participate in this single visit cervix cancer project. Large loop electrosurgical excision procedure (LEEP) was performed on SVP subjects with either a diagnosis of HGSIL/AGUS or suspicion of carcinoma. All other subjects with abnormal Papanicolaou smears were referred to our abnormal cytology clinics or received care in the community.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Older than 18 years
  • No history of invasive cervical cancer
  • Not pregnant

Exclusion Criteria:

  • Absence of a cervix
  • Abnormal vaginal bleeding
  • Cervical cancer screening within the previous 12 months
  • A known bleeding disorder
  • Reluctance to be randomized
  • Unwillingness to follow the study protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00237562

United States, California
University of California, Irvine
Orange, California, United States, 92868
Sponsors and Collaborators
University of California, Irvine
National Cancer Institute (NCI)
Principal Investigator: Alberto Manetta, MD University of California, Irvine
  More Information

ClinicalTrials.gov Identifier: NCT00237562     History of Changes
Other Study ID Numbers: R01 CA76501
Study First Received: October 10, 2005
Last Updated: May 4, 2006
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Carcinoma in Situ
Cervical Intraepithelial Neoplasia
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on November 27, 2015